

Effectiveness, safety, and health-related quality of life in moderate-to-severe atopic dermatitis treated with lebrikizumab: A 16-week nationwide retrospective cohort study

Gianluca Avallone^{1,2*}, Andrea Bombelli^{1,2*}, Luigi Gargiulo^{3,4}, Caterina Foti⁵, Ilaria Trave⁶, Mariateresa Rossi⁷, Elisabetta Magnaterra^{8,9}, Flavia Pigliacelli¹⁰, Piergiorgio Malagoli¹¹, Serena Giacalone¹², Antonio Portarapillo¹³, Cataldo Patruno¹⁴, Natale Schettini¹⁵, Laura Bonzano¹⁶, Elena Pezzolo¹⁷, Camilla Chello¹⁸, Niccolò Gori^{19,20}, Giovanna Brunasso²¹, Federica Veronese²², Michela Ortoncelli²³, Ersilia Tolino²⁴, Alan Azzolini²⁵, Francesco Bellinato²⁶, Katharina Hansel²⁷, Eugenia Veronica Di Brizzi²⁸, Carlotta Gurioli²⁹, Maria Esposito³⁰, Roberta Giuffrida³¹, Francesca Barei¹, Paolo Calzari², Anna G Burroni⁶, Massimo Gola⁸, Maria Mariano¹⁰, Maria Concetta Fagnoli¹⁰, Maddalena Napolitano¹³, Teresa Grieco¹⁸, Ketty Peris^{19,20}, Paola Savoia²², Simone Ribero²³, Giampiero Girolomoni²⁶, Luca Stingeni²⁷, Anna Balato²⁸, Antonio Costanzo^{3,4}, Angelo Valerio Marzano^{1,2}, Alessandra Narcisi^{3,4§}, Silvia Mariel Ferrucci^{1§}

*These authors contributed equally to this article and share first authorship

§These authors contributed equally to this article and share senior authorship

Corresponding author:

Gianluca Avallone, MD

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace, 9, 20122, Milan, Italy. Telephone: +390255031

E-mail: gianluca.avallone2@gmail.com

Supplementary Material

Table S1. Patients' evaluation of HRQoL reported as mean DLQI scores at baseline, Week 4, and Week 16.

DLQI categories	Patients n (%)
Baseline	
No effect	0
Small effect	3 (3.9)
Moderate effect	7 (9.0)
Very large effect	18 (23.1)
Extremely large effect	20 (25.6)
Missing information	30 (38.5)
Week 4	
No effect	9 (11.5)
Small effect	6 (7.7)
Moderate effect	12 (15.4)
Very large effect	15 (19.2)
Extremely large effect	1 (1.3)
Missing information	35 (44.9)
Week 16	
No effect	13 (16.7)
Small effect	17 (21.8)
Moderate effect	11 (14.1)
Very large effect	6 (7.7)
Extremely large effect	1 (1.3)
Missing information	30 (38.5)

DLQI categories were defined as follows: 0-1, "no effect on patient's life"; 2-5, "small effect on patient's life"; 6-10, "moderate effect on patient's life"; 11-20, "very large effect on patient's life"; and 21-30, "extremely large effect on patient's life". Abbreviations: DLQI, dermatology life quality index; HRQoL, health related quality of life; n, number.

Table S2. Experienced pruritus levels reported as mean itch-NRS scores at baseline, Week 4, and Week 16 for 78 patients.

Itch-NRS Score	Patients n (%)
Baseline	
0	0
1	1 (1.3)
2	0
3	6 (7.7)
4	1 (1.3)
5	3 (3.9)
6	3 (3.9)
7	12 (15.4)
8	26 (33.3)
9	10 (12.8)
10	15 (19.2)
Missing information	1 (1.3)
Week 4	
0	9 (11.5)
1	3 (3.9)
2	11 (14.1)
3	8 (10.3)
4	14 (18.0)
5	5 (6.4)
6	5 (6.4)
7	3 (3.9)
8	2 (2.6)
9	1 (1.3)
10	0
Missing information	17 (21.8)
Week 16	
0	17 (21.8)
1	7 (9.0)
2	13 (16.7)
3	12 (15.4)
4	7 (9.0)
5	4 (5.1)
6	5 (6.4)
7	5 (6.4)
8	5 (6.4)
9	0
10	1 (1.3)
Missing information	2 (2.6)

Itch-NRS categories were defined as following: 0, “no itch”; 1-2, “mild itch”; 3-6, “moderate itch”; 7-8, “severe itch”; 9-10, “very severe itch”. Abbreviations: n, number; NRS, numerical rating scale.

Table S3. Disease severity reported as mean IGA scores at baseline, Week 4, and Week 16.

IGA score	Patients n (%)
Baseline	
Clear	0
Almost Clear	1 (1.3)
Mild	8 (10.3)
Moderate	41 (52.6)
Severe	23 (29.5)
Missing information	5 (6.4)
Week 4	
Clear	5 (6.4)
Almost Clear	12 (15.4)
Mild	26 (33.3)
Moderate	14 (17.9)
Severe	0
Missing information	21 (26.9)
Week 16	
Clear	8 (10.3)
Almost Clear	34 (43.6)
Mild	16 (20.5)
Moderate	9 (11.5)
Severe	1 (1.3)
Missing information	10 (12.8)

IGA categories were defined as following: 0, “Clear”; 1, “almost clear”; 2, “mild signs”; 3, “moderate signs”; and 4, “severe signs”. Abbreviations: IGA, investigator’s global assessment; n, number.

Table S4. Outcomes stratified by bio/JAKi-experienced and bio/JAKi-naïve and status of patients at baseline, Week 4, and Week 16.

	Bio/JAKi-experienced (n=49)	Bio/JAKi-naïve (n=29)
EASI score		
Baseline		
n	49	29
Mean±SD	19.2±10.9	23.8±7.5
Week 4		
n	38	23
Mean±SD	9.0±6.6	9.2±6.8
Week 16		
n	49	29
Mean±SD	5.2±4.80	5.1±6.4
EASI head & neck score		
Baseline		
n	39	28
Mean±SD	4.1±1.8	2.8±2.2
Week 4		
n	32	24
Mean±SD	2.6±2.1	1.3±1.7
Week 16		
n	40	28
Mean±SD	1.9±1.9	1.0±1.5
DLQI score		
Baseline		
n	28	20
Mean±SD	17.2±7.8	19.2±7.5
Week 4		
n	24	19
Mean±SD	9.5±6.2	7.6±6.3
Week 16		
n	28	20
Mean±SD	5.9±5.4	4.6±5.9
Itch-NRS score		
Baseline		
n	48	29
Mean±SD	7.5±2.1	7.9±2.0
Week 4		
n	37	24
Mean±SD	3.3±2.3	3.5±2.2
Week 16		
n	47	29
Mean±SD	2.7±2.4	3.6±2.9
Sleep-NRS score		

	Bio/JAKi-experienced (n=49)	Bio/JAKi-naïve (n=29)
Baseline		
n	48	29
Mean±SD	5.3±3.5	6.3±3.2
Week 4		
n	37	24
Mean±SD	2.0±2.5	1.8±2.0
Week 16		
n	47	29
Mean±SD	1.2±2.2	2.1±2.8
BSA score (%)		
Baseline		
n	32	24
Mean±SD	29.3±22.0	35.1±20.3
Week 4		
n	22	19
Mean±SD	19.3±17.1	13.7±7.3
Week 16		
n	28	24
Mean±SD	7.4±7.8	7.6±13.8
IGA score, n (%)		
Baseline		
Clear	0	0
Almost Clear	1 (2.0)	0
Mild	6 (12.2)	2 (6.9)
Moderate	24 (49.0)	17 (58.6)
Severe	13 (26.5)	10 (34.5)
Missing information	5 (10.2)	0
Week 4		
Clear	4 (8.2)	1 (3.5)
Almost Clear	7 (14.3)	5 (17.2)
Mild	11 (22.5)	15 (51.7)
Moderate	11 (22.5)	3 (10.3)
Severe	0	0
Missing information	16 (32.7)	5 (17.2)
Week 16		
Clear	6 (12.2)	2 (6.9)
Almost Clear	16 (32.7)	18 (62.1)
Mild	11 (22.5)	5 (17.2)
Moderate	6 (12.2)	3 (10.3)
Severe	0	1 (3.5)
Missing information	10 (20.4)	0
SCORAD score		
Baseline		
n	10	9
Mean±SD	44.0±21.1	61.2±12.0

	Bio/JAKi-experienced (n=49)	Bio/JAKi-naïve (n=29)
Week 4		
n	9	9
Mean±SD	17.8±13.6	27.4±7.6
Week 16		
n	9	9
Mean±SD	7.9±7.6	17.9±16.0
POEM score		
Baseline		
n	20	14
Mean±SD	20.3±7.1	20.1±6.1
Week 4		
n	13	13
Mean±SD	7.6±5.9	7.8±4.9
Week 16		
n	13	14
Mean±SD	6.3±6.0	5.6±5.9
ADTC score		
Baseline		
n	16	12
Mean±SD	16.2±4.3	16.1±5.1
Week 4		
n	13	12
Mean±SD	7.8±5.7	7.3±4.8
Week 16		
n	16	14
Mean±SD	6.1±5.9	3.8±2.7
HADS-A score		
Baseline		
n	11	7
Mean±SD	7.5±6.9	9.1±1.6
Week 4		
n	7	6
Mean±SD	2.4±3.1	3.2±1.0
Week 16		
n	10	7
Mean±SD	2.8±3.6	1.3±1.0
HADS-D score		
Baseline		
n	11	7
Mean±SD	6.7±6.9	10.3±3.6
Week 4		
n	8	6
Mean±SD	2.9±4.1	5.0±2.0
Week 16		

	Bio/JAKi-experienced (n=49)	Bio/JAKi-naïve (n=29)
n	10	7
Mean±SD	3.6±3.5	2.7±1.3
Achievement of MDA, n (%)		
Week 4		
No	21 (42.9)	17 (58.6)
Yes	3 (6.1)	1 (3.5)
Missing information	25 (51.0)	11 (37.9)
Week 16		
No	23 (46.9)	18 (62.1)
Yes	5 (10.2)	2 (6.9)
Missing information	21 (42.9)	9 (31.0)

Abbreviations: ADCT, atopic dermatitis control tool; bio/JAKi, biologic drug or Janus kinase inhibitor; BSA, body surface area; DLQI, dermatology life quality index; EASI, eczema area and severity index; HADS-A, hospital anxiety and depression scale for anxiety; HADS-D, hospital anxiety and depression scale for depression; IGA, investigator's global assessment; MDA, minimal disease activity; ; n, number; NRS, numerical rating scale; POEM, patient-reported eczema measure; SCORAD, scoring atopic dermatitis; SD, standard deviation; .